FLT3 and acute myeloid leukemia: We observed that most patients with FLT3‐ITD mutation clearance following gilteritinib therapy had also achieved CR with prior AML therapy and had a longer duration of response to prior treatment than patients without FLT3‐ITD mutation clearance.